Quantifying muscle asymmetries in cervical dystonia with electrical impedance: A preliminary assessment

Clinical Neurophysiology

Volumn 122, Issue 5, 2011, Pages 1027-1031

  Lungu, Codrin ^a   Tarulli, Andrew W ^b   Tarsy, Daniel ^b   Mongiovi, Phillip ^b   Vanderhorst, Veronique G ^b   Rutkove, Seward B ^b  

^a NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE   (United States)

^b HARVARD MEDICAL SCHOOL   (United States)

Author keywords

Botulinum toxin; Diagnosis; Dystonia; Electrical impedance myography

Indexed keywords

BOTULINUM TOXIN A; BOTULINUM TOXIN B;

ADULT; ARTICLE; CERVICAL DYSTONIA; CERVICAL PARASPINAL MUSCLE; CLINICAL ARTICLE; CONTROLLED STUDY; DIAGNOSTIC ACCURACY; DIAGNOSTIC TEST ACCURACY STUDY; ELECTRIC RESISTANCE; ELECTROMYOGRAPHY; FEMALE; HUMAN; IMPEDANCE; MALE; MUSCLE HYPERTROPHY; NECK MUSCLE; PRIORITY JOURNAL; QUANTITATIVE ANALYSIS; RECEIVER OPERATING CHARACTERISTIC; STERNOCLEIDOMASTOID MUSCLE;

ELECTRIC IMPEDANCE; FEMALE; HUMANS; MALE; MIDDLE AGED; MUSCLE, SKELETAL; MYOGRAPHY; TORTICOLLIS;

EID: 79953023743     PISSN: 13882457     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.clinph.2010.09.013     Document Type: Article

References (33)

1. Borodic G.E., Ferrante R. Effects of repeated botulinum toxin injections on orbicularis oculi muscle. J Clin Neuroophthalmol 1992, 12(2):121-127.
2. Burke R.E., Fahn S., Marsden C.D., Bressman S.B., Moskowitz C., Friedman J. Validity and reliability of a rating scale for the primary torsion dystonias. Neurology 1985, 35(1):73-77.
3. Cano S.J., Hobart J.C., Edwards M., Fitzpatrick R., Bhatia K., Thompson A.J., et al. CDIP-58 can measure the impact of botulinum toxin treatment in cervical dystonia. Neurology 2006, 67(12):2230-2232.
4. Comella C.L., Leurgans S., Wuu J., Stebbins G.T., Chmura T. Dystonia study group. Rating scales for dystonia: a multicenter assessment. Mov Disord 2003, 18(3):303-312.
5. Comella C.L., Stebbins G.T., Goetz C.G., Chmura T.A., Bressman S.B., Lang A.E. Teaching tape for the motor section of the Toronto Western Spasmodic Torticollis Scale. Mov Disord 1997, 12(4):570-575.
6. Consky E., Basinski A., Belle L., Ranawaya R., Lang A.E. The Toronto Western Spasmodic Torticollis Rating Scale (TWSTRS): assessment of validity and inter-rater reliability. Neurology 1990, 40(Suppl. 1):445.
7. Deuschl G., Heinen F., Kleedorfer B., Wagner M., Lücking C.H., Poewe W. Clinical and polymyographic investigation of spasmodic torticollis. J Neurol 1992, 239:9-15.
8. A prevalence study of primary dystonia in eight European countries. J Neurol 2000, 247(10):787-792. Epidemiological Study of Dystonia in Europe (ESDE) Collaborative Group.
9. Esper G.J., Shiffman C.A., Aaron R., Lee K.S., Rutkove S.B. Assessing neuromuscular disease with multifrequency electrical impedance myography. Muscle Nerve 2006, 34(5):595-602.
10. Finsterer J. EMG-interference pattern analysis. J Electromyogr Kinesiol 2001, 11(4):231-246.
11. Jankovic J., Tsui J., Bergeron C. Prevalence of cervical dystonia and spasmodic torticollis in the United States general population. Parkinsonism Relat Disord 2007, 13(7):411-416.
12. Matic D.B., Lee T.Y., Wells R.G., Gan B.S. The effects of botulinum toxin type A on muscle blood perfusion and metabolism. Plast Reconstr Surg 2007, 120(7):1823-1833.
13. Ogunnika O.T., Scharfstein M., Cooper R.C., Ma H., Dawson J.L., Rutkove S.B. Handheld electrical impedance myography probe for the assessment of neuromuscular disease. Conf Proc IEEE Eng Med Biol Soc 2008, 2008:3566-3569.
14. Ostrem J.L., Starr P.A. Treatment of dystonia with deep brain stimulation. Neurotherapeutics 2008, 5(2):320-330.
15. Pretto T.E., Dalvi A., Kang U.J., Penn R.D. A prospective blinded evaluation of deep brain stimulation for the treatment of secondary dystonia and primary torticollis syndromes. J Neurosurg 2008, 109(3):405-409.
16. Rutkove S.B., Aaron R., Shiffman C.A. Localized bioimpedance analysis in the evaluation of neuromuscular disease. Muscle Nerve 2002, 25:390-397.
17. Rutkove S.B., Esper G.J., Lee K.S., Aaron R., Shiffman C.A. Electrical impedance myography in the detection of radiculopathy. Muscle Nerve 2005, 32(3):335-341.
18. Rutkove S.B., Lee K.S., Shiffman C.A., Aaron R. Test-retest reproducibility of 50kHz linear-electrical impedance myography. Clin Neurophysiol 2006, 117(6):1244-1248.
19. Rutkove S.B., Zhang H., Schoenfeld D.A., Raynor E.M., Shefner J.M., Cudkowicz M.E., et al. Electrical impedance myography to assess outcome in ALS clinical trials. Clin Neurophysiol 2007, 118:2413-2418.
20. Rutkove S.B. Electrical impedance myography: background, current state, and future directions. Muscle Nerve 2009, 40(6):936-946.
21. Schroeder A.S., Ertl-Wagner B., Britsch S., Schröder J.M., Nikolin S., Weis J., et al. Muscle biopsy substantiates long-term MRI alterations one year after a single dose of botulinum toxin injected into the lateral gastrocnemius muscle of healthy volunteers. Mov Disord 2009, 24(10):1494-1503.
22. Shiffman C.A., Aaron R., Amoss V., Therrien J., Coomler K. Resistivity and phase in localized BIA. Phys Med Biol 1999, 44:2409-2429.
23. Simpson D.M., Blitzer A., Brashear A., Comella C., Dubinsky R., Hallett M., et al. Assessment: botulinum neurotoxin for the treatment of movement disorders (an evidence-based review): report of the Therapeutics and Technology Assessment Subcommittee of the American Academy of Neurology. Neurology 2008, 70(19):1699-1706.
24. Singer C., Velickovic M. Cervical dystonia: etiology and pathophysiology. Neurol Clin 2008, 26(Suppl. 1):9-22.
25. Stacy M. Epidemiology, clinical presentation, and diagnosis of cervical dystonia. Neurol Clin 2008, 26(Suppl. 1):23-24.
26. Tarsy D. Comparison of clinical rating scales in treatment of cervical dystonia with botulinum toxin. Mov Disord 1997, 12(1):100-102.
27. Tarulli A., Esper G.J., Lee K.S., Aaron R., Shiffman C.A., Rutkove S.B. Electrical impedance myography in the bedside assessment of inflammatory myopathy. Neurology 2005, 65(3):451-452.
28. Tarulli A.W., Duggal N., Esper G.J., Garmirian L.P., Fogerson P.M., Lin C.H., et al. Electrical impedance myography in the assessment of disuse atrophy. Arch Phys Med Rehabil 2009, 90(10):1806-1810.
29. Tarulli A.W., Garmirian L.P., Fogerson P.M., Rutkove S.B. Localized muscle impedance abnormalities in amyotrophic lateral sclerosis. J Clin Neuromuscul Dis 2009, 10(3):90-96.
30. Tinazzi M., Squintani G., Berardelli A. Does neurophysiological testing provide the information we need to improve the clinical management of primary dystonia?. Clin Neurophysiol 2009, 120(8):1424-1432.
31. Tolosa E.S., Marti M.J. Adult-Onset Idiopathic Torsion Dystonias. Neurologic Principles and Practice 2004, 511-526. McGraw-Hill. 2nd ed. R.L. Watts, W.C. Koller (Eds.).
32. Vercueil L. Les échelles cliniques de la dystonie. Rev Neurol (Paris) 2003, 159(10 pt. 1):906-915.
33. Zweig M.H., Campbell G. Receiver-operating characteristic (ROC) plots: a fundamental evaluation tool in clinical medicine. Clin Chem 1993, 39(4):561-577. Erratum in: Clin Chem 1993;39(8):1589.